allogen
haematopoiet
stem
cell
transplant
hsct
potenti
cur
procedur
varieti
pediatr
hematolog
disord
posttranspl
infect
contribut
significantli
morbid
associ
procedur
ablat
hsct
recipi
immun
system
condit
regimen
increas
suscept
infect
reach
immun
reconstitut
donor
stem
cell
morbid
mortal
respiratori
virus
immunocompromis
patient
includ
undergo
hsct
well
establish
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
influenza
human
metapneumoviru
hmpv
recent
data
suggest
common
human
coronavirus
hcov
also
associ
signific
mortal
similar
seen
rsv
piv
less
inform
regard
infect
caus
human
rhinovirus
hrv
human
bocaviru
hbov
natur
killer
nk
cell
nasal
secret
first
line
defens
respiratori
virus
healthi
individu
undergo
hsct
protect
role
mani
viral
infect
commonli
encount
hsct
includ
herp
simplex
viru
varicellazost
viru
cytomegaloviru
influenza
viru
well
bacteri
nk
cell
play
import
role
host
immun
defens
product
cytotox
granul
contain
molecul
perforin
granzym
lyse
infect
cell
import
featur
nk
cell
product
cytokin
includ
interferon
enhanc
local
immun
respons
directli
act
target
cell
role
recruit
activ
immun
cell
includ
cell
nk
cell
recogn
viral
infect
cell
integr
signal
activ
inhibitori
germ
line
encod
receptor
nk
cell
membran
bound
killercel
activ
receptor
kar
work
togeth
inhibitori
killer
immunoglobulinlik
receptor
kir
order
regul
nk
cell
function
infect
transform
cell
interact
kir
famili
nk
cell
hla
class
molecul
result
inhibitori
signal
kar
like
natur
cytotox
receptor
ncr
compris
key
receptor
recognit
elimin
viral
infect
tumor
immun
cell
nasal
mucosa
control
regul
viral
infect
via
kill
infect
respiratori
epitheli
cell
low
number
nk
cell
nasopharyng
aspir
npa
hsct
pediatr
recipi
could
associ
increas
suscept
viral
respiratori
infect
although
blood
immun
reconstitut
hsct
wide
littl
known
immun
reconstitut
hsct
recipi
mucosa
present
studi
goal
determin
nk
cell
number
nasal
passag
hsct
recipi
determin
activ
phenotyp
npa
nk
cell
use
multiparametr
flow
cytometri
determin
presenc
function
profil
cell
within
context
viral
infect
assess
effect
viral
infect
nasal
immun
reconstitut
prospect
studi
includ
patient
year
age
receiv
allogen
hsct
la
paz
univers
hospit
madrid
spain
januari
june
exclus
criteria
includ
chronic
lung
diseas
prior
hsct
hsct
perform
accord
current
centr
protocol
use
bone
marrow
peripher
blood
stem
cell
haematopoiet
stem
cell
sourc
acut
chronic
graft
versu
host
diseas
gvhd
defin
grade
previous
age
sexmatch
control
recruit
among
healthi
patient
undergo
elect
surgeri
case
control
also
match
accord
procedur
date
hsct
elect
surgeri
respect
week
research
perform
accord
local
regul
inform
consent
accord
declar
helsinki
obtain
parent
children
studi
approv
clinic
research
ethic
committe
la
paz
univers
hospit
studi
sampl
peripher
blood
pb
npa
collect
prior
condit
regimen
hsct
day
pb
mononuclear
cell
condit
regimen
day
hsct
npa
follow
test
perform
sampl
type
pb
total
nk
cell
countsnpa
total
nk
cell
count
natur
cytotox
receptor
viral
detect
npa
collect
ml
salin
solut
instil
nostril
nasopharynx
suction
use
steril
cathet
mucu
trap
npa
perform
patient
activ
bleed
platelet
count
npa
sampl
contain
blood
consid
valid
discard
specimen
sent
respiratori
viru
influenza
unit
nation
microbiolog
center
isciii
madrid
spain
viral
analysi
translat
research
paediatr
oncolog
hematopoiet
transplant
cell
therapi
unit
la
paz
hospit
research
institut
madrid
spain
flow
cytometri
assay
npa
process
within
hour
collect
control
group
npa
collect
day
surgeri
upon
recept
sampl
three
aliquot
prepar
store
recept
npa
sampl
process
area
separ
defin
work
area
three
independ
rtpcr
assay
perform
detect
sixteen
respiratori
virus
previous
publish
influenza
b
c
virus
detect
use
previous
describ
primer
set
amplifi
influenza
virus
multiplex
pcr
second
multiplex
pcr
use
detect
parainfluenza
virus
human
coronavirus
enterovirus
presenc
rsv
b
type
hmpv
hbov
adenovirus
establish
use
third
multiplex
rtnest
flow
cytometri
assay
npa
sampl
filter
cell
strainer
falcon
centrifug
rpm
min
suspend
pb
total
sampl
volum
acquir
use
navio
flow
cytomet
beckman
coulter
total
cell
count
per
sampl
determin
cell
natur
killer
nk
cell
popul
identifi
use
follow
label
antibodi
clone
bd
pharmingen
clone
bd
pharmingen
clone
biolegend
fluoresc
cell
viabil
dye
bd
pharmingen
use
exclud
dead
cell
flowjo
softwar
treestar
use
data
analysi
express
natur
cytotox
receptor
ncr
receptor
nk
cell
subpopul
npa
evalu
follow
fluorochromeconjug
antibodi
clone
miltenyibiotec
clone
abdserotec
clone
bd
pharmingen
clone
miltenyibiotec
clone
r
system
biolegend
valu
express
percentag
discret
variabl
median
interquartil
rang
iqr
continu
variabl
comparison
group
control
hsct
patient
condit
patient
without
viral
respiratori
infect
made
use
mannwhitney
u
test
fisher
exact
test
appropri
valu
p
consid
statist
signific
analys
perform
use
spss
statist
softwar
version
ibm
corp
studi
period
hsct
recipi
recruit
main
characterist
summar
tabl
median
age
patient
year
iqr
hsct
allogen
twentyf
patient
underw
hsct
first
time
two
receiv
second
hsct
eighteen
healthi
children
includ
control
group
male
femal
median
age
year
iqr
signific
differ
regard
age
sex
hsct
recipi
healthi
control
total
sampl
collect
hsct
recipi
valid
viral
studi
median
number
valid
sampl
per
patient
iqr
twentyf
sampl
posit
hsct
recipi
least
one
viral
detect
among
hsct
recipi
viral
infect
median
number
posit
sampl
per
patient
iqr
hrv
isol
sampl
posit
npa
patient
follow
adenoviru
parainfluenza
type
two
posit
sampl
two
differ
patient
viral
coinfect
among
hsct
recipi
detail
inform
regard
posit
sampl
given
tabl
infect
caus
hrv
symptomat
patient
one
lowgrad
fever
persist
rhinorrhea
patient
adenoviru
infect
fever
mucos
elev
level
creactiv
protein
mgl
infect
parainfluenza
type
viru
also
symptomat
one
patient
fever
anoth
laryng
pneumonia
none
patient
requir
admiss
intens
care
unit
icu
die
result
viral
infect
differ
regard
age
hsct
recipi
without
viral
infect
median
iqr
year
age
respect
p
patient
two
year
age
test
posit
frequent
sampl
vs
p
total
sampl
healthi
control
analyz
virus
identifi
two
singl
infect
hrv
adenoviru
two
coinfect
hrv
hbov
hrv
adenoviru
tabl
control
viral
infect
younger
differ
reach
statist
signific
median
iqr
vs
year
p
infect
asymptomat
signific
differ
found
regard
viral
isol
rate
patient
healthi
control
sampl
respect
p
npa
patient
prior
hsct
condit
contain
fewer
nk
cell
compar
healthi
control
p
p
respect
fig
addit
pcr
patient
prior
hsct
condit
show
statist
signific
higher
number
nk
cell
npa
patient
p
differ
observ
healthi
control
cell
popul
isol
npa
analyz
nk
cell
kinet
hsct
observ
increas
cell
npa
sampl
infus
day
increas
revert
day
post
hsct
npa
cell
count
reach
level
similar
observ
prior
hsct
effect
observ
pcr
patient
fig
suppl
tabl
howev
observ
peak
nk
cell
differ
regard
npa
nk
cell
count
time
patient
without
respiratori
infect
prior
hsct
initi
cell
count
higher
pcr
patient
patient
median
iqr
vs
p
fig
suppl
tabl
howev
pcr
patient
similar
initi
nk
cell
count
prior
hct
median
iqr
vs
median
cell
count
decreas
notabl
hsct
pcr
patient
day
post
hsct
number
still
far
initi
valu
effect
observ
pb
nk
cell
count
either
nk
cell
found
npa
sampl
highli
activ
statu
determin
flow
cytometri
analysi
fig
percentag
nk
cell
express
differ
activ
receptor
higher
pcr
npa
sampl
sampl
receptor
analyz
especi
signific
receptor
fig
highli
activ
statu
observ
healthi
donor
hsct
patient
npa
outcom
hsct
recipi
summar
tabl
signific
differ
accord
presenc
viral
infect
number
nk
cell
patient
npa
pre
afterhsct
correl
higher
risk
gvhd
graft
failur
icu
admiss
death
suppl
tabl
nasal
mucosa
first
place
within
respiratori
system
expos
inhal
viral
pathogen
therefor
nasal
immun
cell
like
play
import
role
earli
innat
immun
respons
environment
factor
healthi
individu
immunocompromis
patient
like
hsct
recipi
nk
cell
thought
play
particularli
import
role
context
sinc
abl
influenc
innat
adapt
immun
first
lymphocyt
subset
appear
pb
macrophag
dendrit
cell
identifi
nasal
neutrophil
identifi
nasal
immun
cell
present
npa
fulli
character
phenotyp
npa
cell
previou
research
reli
cell
differenti
analysi
cytocentrifug
slide
stain
haematoxylin
eosin
howev
flow
cytometri
may
superior
method
fulli
character
npa
immun
cell
sinc
allow
precis
quantif
cell
popul
well
phenotyp
studi
make
possibl
determin
activ
statu
specif
cell
popul
studi
show
hsct
patient
expect
due
condit
regimen
underli
diseas
fewer
nk
cell
npa
compar
healthi
control
interestingli
patient
expos
viral
pathogen
show
statist
signific
higher
nk
cell
count
npa
accord
role
front
line
defens
viral
infect
phenotyp
function
nk
cell
differ
depend
sourc
organ
current
research
explor
particular
phenotyp
nasal
nk
cell
show
higher
activ
statu
found
pb
compar
result
obtain
studi
previou
public
especi
true
individu
posit
viral
detect
nasal
secret
okada
et
al
recent
report
nk
cell
found
nasal
passag
mice
belong
convent
nk
cell
linag
characterist
demonstr
immatur
activ
result
constitut
first
evid
observ
human
studi
observ
unexpect
cell
increas
npa
hsct
day
sampl
despit
condit
regimen
attribut
fact
npa
sampl
collect
morn
almost
patient
receiv
nonmanipul
graft
cohort
finish
infus
prior
npa
collect
pretranspl
condit
highdos
chemotherapi
toxic
mani
cell
render
endothelium
could
lead
increas
cell
npa
mani
patient
natur
killer
cell
activ
regul
balanc
signal
inhibitori
activ
receptor
natur
cytotox
receptor
ncr
well
main
activ
receptor
involv
mediat
nk
cell
function
health
overexpress
activ
receptor
found
nk
cell
npa
consist
shemeravni
et
al
nasal
lavag
sampl
patient
infect
respiratori
virus
found
abundantli
express
ncr
howev
rtqpcr
analysi
detect
express
littl
altogeth
find
point
key
player
nasal
mucosa
elimin
viral
infect
cell
nk
cell
condit
regimen
use
allogen
hsct
high
dose
chemotherapi
andor
radiotherapi
induc
seriou
damag
mucos
humor
cellular
immun
function
moreov
regimen
harm
host
thymopoiesi
result
delay
immun
collect
factor
predispos
host
varieti
infect
fact
despit
routin
use
prophylact
antimicrobi
peritranspl
infect
occur
hsct
recipi
one
lead
caus
nonrelapserel
mortal
allogen
half
hsct
recipi
includ
studi
present
viral
respiratori
infect
point
date
studi
infect
pediatr
hsct
recipi
focus
symptomat
individu
report
incid
asymptomat
respiratori
infect
children
undergo
hsct
bare
studi
prospect
studi
patient
detect
respiratori
virus
hsct
mainli
hrv
seri
infect
caus
hrv
common
associ
increas
morbid
find
concord
report
srinivasan
et
al
children
cancer
posthsct
upper
lower
respiratori
asymptomat
children
author
report
implement
routin
extens
prehsct
lung
screen
includ
bronchoalveolar
lavag
detect
virus
bacteria
fungi
studi
almost
one
third
asymptomat
patient
viral
respiratori
infect
mainli
caus
rhinoviru
none
worsen
hand
infect
caus
adenoviru
parainfluenza
viru
less
frequent
often
symptomat
patient
adenoviru
describ
caus
lower
respiratori
tract
infect
high
mortal
hsct
studi
involv
symptomat
find
correl
viral
infect
hsct
outcom
could
caus
small
sampl
size
low
incid
symptomat
infect
import
strength
studi
includ
prospect
design
determin
number
activ
phenotyp
function
profil
nk
cell
togeth
respiratori
viru
detect
assess
hsct
recipi
time
compar
healthi
control
potenti
limit
studi
relat
sampl
size
loss
followup
npa
cell
count
great
variabl
larger
cohort
would
desir
draw
stronger
conclus
mani
patient
toler
well
npa
withdrew
cours
studi
small
number
patient
preclud
correl
viral
detect
transplant
outcom
limit
abil
examin
implic
asymptomat
viral
respiratori
infect
hsct
recipi
npa
collect
day
hsct
infect
occur
later
may
miss
howev
respiratori
viral
infect
hsct
recipi
occur
soon
transplant
advers
clinic
outcom
like
occur
conclus
provid
data
suggest
nk
cell
major
effector
respiratori
viral
control
nasal
mucosa
also
character
nk
cell
popul
find
highli
activ
phenotyp
compar
pb
counterpart
studi
uniqu
mucos
immun
cell
popul
benefici
assess
effect
viral
infect
upper
respiratori
immun
respons
hsct
recipi
well
healthi
individu
